CorVin Clinical
ActiveCorVin Clinical has been active since 2020 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €52k and a net result of €71k. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 45% of 518 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.7% (low).
Checked score
Score 2025
100
/ 100
Excellent▲ +17 vs 2024
The score combines four axes. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability100=
Solvency97▲+13
Growth78=
Stability94
Bankruptcy probability, 12 months
0.7%
Low
0%0.5%1.5%4%10%≥ 25%
Credit up to €5k at 30 days acceptable
Liquidity ample (current ratio 2.47 against 1.83 in 2024), and 43.5% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Limited track record
This company has not been active as long as an established one and statistically fails somewhat more often.
KBO · incorporation dateAge against the risk zone
lowers risk · Lower-failure-rate sector
In this sector companies fail less often than the Belgian average.
Gazette · bankruptcies per sector, NACE 72
Relative position
BE, all sectors
reference
Sector 72
lower
← fewer bankruptcies
more bankruptcies →
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
56.5%
Return on assets
76.9%
Age of the figures
8 mo
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 29-07-2026, 2 days ahead of the deadline.
NBB · 6 filingsDeviation from the deadline
2025
2 d early
2024
23 d early
2023
7 d early
2022
26 d early
2021
33 d early
2020
32 d early
← before the deadline
after the deadline →
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
15-09-2026 today31-12-2026 close31-07-2027 deadline
Financials · fiscal year 2025, micro schema
Equity
€52k▲ 67.0%
2024 · €31k
2020: €8k
2021: €67k
2022: €121k
2023: €71k
2024: €31k
2020 → 2025
Total assets
€92k▲ 26.8%
2024 · €73k
2020: €10k
2021: €74k
2022: €135k
2023: €110k
2024: €73k
2020 → 2025
Net result
€71k▲ 18.4%
2024 · €60k
2020: €-2k
2021: €60k
2022: €55k
2023: €65k
2024: €60k
2020 → 2025
Working capital
€55k▲ 67.3%
2024 · €33k
2020: €8k
2021: €66k
2022: €120k
2023: €71k
2024: €33k
2020 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20212022202320242025Trend
Equity€67k-€121k▲ 80.8%€71k▼ 41.1%€31k▼ 56.2%€52k▲ 67.0%
Operating result€77k-€71k▼ 7.5%€84k▲ 18.1%€78k▼ 6.8%€92k▲ 17.5%
Net result€60k-€55k▼ 8.9%€65k▲ 18.6%€60k▼ 8.3%€71k▲ 18.4%
Turnover and EBIT margin not published: the micro schema does not require them.
Result per fiscal year
Operating resultNet result
The operating result recovers in 2025; 2025 is 18% above 2024 and is the highest year so far.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €92k
Fixed assets
€264▼ 68.4%
Current assets
€92k▲ 27.9%
Equity and liabilities €92k
Equity
€52k▲ 67.0%
Debt
€40k▼ 3.4%
The debt ratio falls from 57.1% to 43.5%: equity grows while debt is paid down.
Key figures and ratios
EBITDA
€92k▲
2024 · €79k
Cash flow
€72k▲
2024 · €61k
Solvency
56.5%▲
2024 · 42.9%
Current ratio
2.47▲
2024 · 1.83
Quick ratio
2.47▲
2024 · 1.83
Debt / equity
0.77▼
2024 · 1.33
ROE
135.9%▼
2024 · 191.7%
ROA
76.9%▼
2024 · 82.3%
Interest coverage
495.84▼
2024 · 909.96
Debt
€40k▼
2024 · €42k
Debt ≤ 1 year
€37k▼
2024 · €39k
Income taxes
€21k▲
2024 · €18k
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2025 against 2024
Balance sheet
Code20242025
Assets
Total assets20/58€73k€92k▲
Fixed assets21/28€835€264▼
Tangible fixed assets22/27€835€264▼
Furniture and vehicles24€835€264▼
Current assets29/58€72k€92k▲
Amounts receivable within one year40/41€37k€38k▲
Trade receivables40€36k€38k▲
Other amounts receivable41€643€0▼
Cash at bank and in hand54/58€35k€52k▲
Deferred charges and accrued income490/1€109€2k▲
Equity and liabilities
Total equity and liabilities10/49€73k€92k▲
Equity10/15€31k€52k▲
Contributions10/11€10k€10k=
Profit (loss) carried forward14€21k€42k▲
Amounts payable17/49€42k€40k▼
Amounts payable within one year42/48€39k€37k▼
Trade debts44€4k€3k▼
Suppliers440/4€4k€3k▼
Taxes, remuneration and social security45€21k€4k▼
Taxes450/3€19k€2k▼
Remuneration and social security454/9€2k€2k▼
Other amounts payable47/48€15k€31k▲
Accrued charges and deferred income492/3€2k€3k▲
Income statement
Code20242025
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€828€571▼
Other operating charges640/8€854€939▲
Gross operating margin9900€80k€93k▲
Operating profit (loss)9901€78k€92k▲
Financial charges65/66B€87€186▲
Recurring financial charges65€87€186▲
Profit (loss) for the period before taxes9903€78k€92k▲
Income taxes67/77€18k€21k▲
Profit (loss) for the period9904€60k€71k▲
Profit (loss) for the period to be appropriated9905€60k€71k▲
Appropriation of the result
Profit (loss) to be appropriated9906€121k€92k▼
Profit (loss) brought forward from the previous period14P€61k€21k▼
Profit to be distributed694/7€100k€50k▼
Return on contributions (dividend)694€100k€50k▼
The notes to these accounts (5 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
29-07
NBB filing
Annual accounts filed
fiscal year 2025 · micro schema
2025
31-12
Financial
Highest result since 2020net €71k ▲18.4%
Operating result €92k, net result €71k, both a record.
08-07
NBB filing
Annual accounts filed
fiscal year 2024 · micro schema
2024
24-07
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema
2023
05-07
NBB filing
Annual accounts filed
fiscal year 2022 · micro schema
2022
31-12
Financial
Equity above €100kEq €121k ▲80.8%
2 profitable years in a row build equity to €121k.
28-06
NBB filing
Annual accounts filed
fiscal year 2021 · micro schema
2021
31-12
Financial
Back to profitnet €60k
Net result €60k after one loss-making year.
31-12
Financial
Liquidity triplescurrent ratio 12.25
Current ratio from 4.01 to 12.25.
29-06
NBB filing
Annual accounts filed
fiscal year 2020 · micro schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
1 act for this company is in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Wetteren · 1 establishment unit since 2020
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Koningshof 179230 WetterenGround area
560 m²
Building footprint
111 m²
Volume, LiDAR
9 m³
Parcel 42025G1180/00S000, Flanders · tallest building 0.9 m. Linked by address, not a title deed.
1 establishment unit
CorVin Clinical
since 20202.311.470.309
1 parcel
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 42025G1180/00S000 | Flanders | 560 m² | 1 · 111 m² | 0.9 m |
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Public money · subsidies and aid
Flemish government
2022 · 1 entry · 5,208 EUR awarded · 5,208 EUR paid| Year | Entries | awarded | paid |
|---|---|---|---|
| 2022 | 1 | 5,208 EUR | 5,208 EUR |
Schemes
Subsidie voor opleiding en advies voor kmo's en zelfstandigen (kmo-portefeuille)
Similar companies · same sector, comparable size
MEDISEARCH INTERNATIONAL
BE 0447.598.679
Bree · Eq €53k
LR Data Science
BE 0542.542.972
Hannut · Eq €51k
STAPHYT BELGIQUE
BE 0667.898.646
Perwez · Eq €51k
GS - TECHNOLOGIES
BE 0461.625.275
Evergem · Eq €50k
AETHER RENEWABLE CHEMICALS
BE 0784.345.661
Gent · Eq €50k
Of 1,174 companies in sector 72109 we hold annual accounts for 712. 375 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded16-12-2020
Fiscal year end31-12
Activities, NACEBEL
72109Other research and development on natural sciences
72101Research and development on biotechnology
86905Human health activities
86951Physiotherapy
Sources
Crossroads Bank for EnterprisesNational Bank · 6 filingsAddress and cadastre registers
Data from official sources, last processed on 15-09-2026. Scores and ratios are computed by Checked and are not a credit decision.